Overview
- The company topped first-quarter estimates as revenue rose 23% on stronger-than-expected procedure growth.
- Worldwide procedures increased about 17%, and Intuitive placed 431 da Vinci systems, bringing the installed base to 11,395 as of March 31.
- Instruments and accessories sales reached $1.69 billion, with systems revenue at $651 million, reflecting broader adoption of da Vinci and Ion platforms.
- Management raised its 2026 da Vinci procedure growth outlook to 13.5% to 15.5% and guided gross margins to 67.5% to 68.5%.
- Regulatory scrutiny continues as the FDA reviews issues with certain curved‑tip staplers after a March 11 customer notice, citing four serious injuries and one death linked to incomplete staple lines.